FDA approves brain-cancer imaging drug Pixclara
The U.S. Food and Drug Administration approved Telix Pharmaceuticals' Pixclara for brain-cancer imaging. The approval concerns a medical diagnostic product rather than a broad emergency or public hazard.
By DoomRadar · Published on DoomRadar .
Why it matters
The decision may affect access to a new diagnostic tool, but it does not indicate a wider public-safety crisis.
Related source links
These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.
- Telix Pharmaceuticals Shares Soar 11.26% as FDA Approves Its Novel Pixclara Brain Cancer Imaging Drug ↗ibtimes.com.au · Recorded source date: Sep 15, 2026, 1:31 AM UTC
AI-assisted, source-based analysis. Methodology · Report a correction